Physician profile
Ani Cioffo
NPI 1699267138
$1,021.65
in general payments reported to CMS, 2019-2025
12 companies · $216 in 2025
The $216 reported for 2025 was more than what a typical Adult Health (Nurse Practitioner) provider received nationally (typical 2025 total: $182).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $440 · 2022: $266 · 2023: $45.55 · 2024: $54.59 · 2025: $216.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $217 · Education: $99.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $216.64 |
| Education | $99.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Takeda Pharmaceuticals U.S.A., INC. | $384.78 | 2021-2025 | Ninlaro |
| Amgen INC. | $297.99 | 2021-2022 | |
| Janssen Biotech, INC. | $129.88 | 2024-2025 | Darzalex, Tecvayli, Talvey |
| Karyopharm Therapeutics INC. | $44.63 | 2021-2023 | Xpovio |
| Genzyme Corporation | $36.59 | 2024-2025 | |
| Pharmacyclics LLC, An Abbvie Company | $26.51 | 2022 | |
| Regeneron Healthcare Solutions, INC. | $21.37 | 2025 | Lynozyfic |
| Glaxosmithkline, LLC. | $20.77 | 2025 | Blenrep |
| Beone Medicines USA, INC. | $18.45 | 2025 | Brukinsa |
| Legend Biotech USA INC. | $14.31 | 2023 | Carvykti |
| Astrazeneca Pharmaceuticals LP | $13.70 | 2023 | Imfinzi |
| Boston Scientific Corporation | $12.67 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ani Cioffo listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.